Discover
KRON
Kronos Bio, Inc.
0.88
undefined x undefined
undefined x undefined
bid
ask
+
0.88
0.00%
07:00 PM
| Ytd | ||
| 1y |
day range
52 week range
| Open | Prev Close | Low | High | Mkt Cap | N/A | ||||
| Vol | 0.00 | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -0.69 |
| Beta | 1.86 | Short Ratio | 8.81 | Inst. Own | 32.67% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 2.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.26 | -0.23 | 0.03 | 11.54% |
| 2024-08-08 | 2024-06 | -0.32 | -0.27 | 0.05 | 15.63% |
| 2024-08-08 | 2024-06 | -0.32 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.43 | -0.5 | -0.07 | -16.28% |
| 2024-05-09 | 2024-03 | -0.43 | N/A | N/A | N/A |
| 2024-03-21 | 2023-12 | -0.51 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-01 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-12-19 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2023-12-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-11-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-07-05 | AL-WAKEEL YASIR B | Chief Financial Officer | 346.10K | Sale |
| 2024-06-27 | BISCHOFBERGER NORBERT W | Chief Executive Officer | 0.00 | Purchase |
| 2024-01-03 | DIMARTINO JORGE M.D. PH.D. | Officer | 315.25K | Sale |
| 2024-01-03 | DINSMORE CHRISTOPHER | Officer | 260.97K | Sale |
| 2024-02-20 | FRISBEE ALLISON | Officer | 204.51K | Sale |
| 2024-06-02 | KNOBELMAN DEBORAH A | Chief Financial Officer | 164.26K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vida Ventures Advisors, LLC | 2.77M | 2.63M | 4.58% |
| 2024-09-29 | Millennium Management Llc | 2.05M | 1.94M | 3.39% |
| 2024-09-29 | Vanguard Group Inc | 1.92M | 1.83M | 3.19% |
| 2024-09-29 | Partners Capital Investment Group, LLP | 1.61M | 1.53M | 2.67% |
| 2024-09-29 | Alphabet Inc. | 1.44M | 1.37M | 2.38% |
| 2024-09-29 | Acadian Asset Management. LLC | 1.30M | 1.24M | 2.16% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.32M | 1.25M | 2.19% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 559.54K | 531.56K | 0.93% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 244.19K | 231.98K | 0.40% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 118.93K | 112.98K | 0.20% |
| 2024-10-30 | iShares Micro Cap ETF | 100.15K | 95.14K | 0.17% |
| 2024-10-30 | Fidelity Total Market Index Fund | 76.51K | 72.68K | 0.13% |
Split
| Split | Date |
|---|---|
| 1.5 : 1 | 2003-11-03 |
| 1.5 : 1 | 2001-11-16 |
| 1.5 : 1 | 1999-03-10 |